晚期前列腺癌中AR变化的临床影响:一个多机构合作
Tanya Dorff1, Zeynep Zengin1, Nicholas Henderson2
1City of Hope.
Research square
|August 23, 2023
概括
在割抵抗性前列腺癌 (CRPC) 患者中,雄激素受体 (AR) 基因放大与在雄激素受体向剂 (ARTA) 治疗期间更长的无进展生存时间有关. 需要进一步的研究来优化ARTA治疗策略对AR改变的患者.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在受体抑制和受体向剂 (ARTA) 的选择性压力下,可以出现雄激素受体 (AR) 基因变异.
- 关于ARTA治疗疗效和患者结局的这些ARTA变化的临床意义仍然不完全理解.
研究的目的:
- 为了调查AR基因变异在割抵抗性前列腺癌 (CRPC) 患者的患病率.
- 评估接受ARTA治疗的患者ARTA变化和临床结果之间的关联.
主要方法:
- 进行了前列腺癌精准医学多机构协作努力 (PROMISE) 数据库的回顾性分析.
- 对540名接受ARTA治疗的CRPC患者的基因组测试数据和临床结果进行了分析.
- 患者根据基因组测试时间 (ARTA治疗前或后) 进行了分层.
主要成果:
- 在ARTA前的患者中,分别在8.2%和13.1%的患者中检测到AR突变和放大.
- 与没有AR变化的患者 (9.6个月;p=0.03) 相比,在ARTA前AR增强患者的进展时间较长 (25.7个月).
- 在ARTA治疗后,分别在18.5%和35.7%的患者中观察到AR突变和放大,L702H是最常见的突变 (9.9%).
结论:
- 这项研究代表了在接受ARTA治疗的CRPC患者中AR改变的最大的现实世界临床基因组分析.
- 在初始ARTA治疗期间,AR放大与进展时间的改善有关.
- 有必要进行前性研究,以完善CRPC患者的治疗策略,这些患者具有特定的AR变化.
相关概念视频
Disorders of the Male Reproductive System
457
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
457
Aortic Regurgitation III: Medical Management
25
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
25
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Cancer Survival Analysis
383
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
383


